VANCOUVER, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, announces that it has entered into agreements to settle an aggregate of $235,908.60 in outstanding obligations through the issuance of common shares of the Company (the “Settlement Shares”) at a deemed price of $0.175 per share, based on the closing price of the Company's commo ...